Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Sep 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Heparin-induced Thrombocytopenia (HIT), which can happen when patients develop a reaction to a blood thinner called heparin. The researchers want to better understand how certain blood cells, called platelets and leukocytes (a type of white blood cell), interact in patients suspected of having this condition. They aim to develop a new test that can quickly confirm HIT without needing more invasive procedures or long wait times for results. This is important because patients with HIT need immediate treatment to prevent serious complications.

To participate in the trial, you need to be an adult over 18 years old who has been suspected of having HIT and has tested positive for specific antibodies related to this condition. If you join the study, you’ll provide blood samples at different times during your hospital stay, and you will continue to receive standard care. The researchers hope that their findings will lead to faster and more reliable testing for HIT, ultimately improving patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • Any adult patient suspected of having HIT, with a positive anti-PF4/H antibody test
• • Patient signed consent to study participation
• • Patient with social security coverage
• Exclusion Criteria:
• • All adult patients with suspected HIT and negative anti-PF4/H antibody test.
• • Protected adults (guardianship, under curators) or deprived of liberty